Deutsche Bank AG Boosts Holdings in Dynavax Technologies Co. (NASDAQ:DVAX)

Deutsche Bank AG increased its position in shares of Dynavax Technologies Co. (NASDAQ:DVAX - Free Report) by 49.3% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 126,398 shares of the biopharmaceutical company's stock after buying an additional 41,720 shares during the period. Deutsche Bank AG owned 0.10% of Dynavax Technologies worth $1,614,000 as of its most recent filing with the SEC.

Other hedge funds have also recently added to or reduced their stakes in the company. D. E. Shaw & Co. Inc. boosted its stake in shares of Dynavax Technologies by 34.0% during the 4th quarter. D. E. Shaw & Co. Inc. now owns 1,918,340 shares of the biopharmaceutical company's stock worth $24,497,000 after acquiring an additional 486,981 shares in the last quarter. Deerfield Management Company L.P. Series C increased its holdings in Dynavax Technologies by 23,990.1% in the 4th quarter. Deerfield Management Company L.P. Series C now owns 5,193,823 shares of the biopharmaceutical company's stock worth $66,325,000 after acquiring an additional 5,172,263 shares in the last quarter. Deep Track Capital LP raised its position in Dynavax Technologies by 42.0% during the fourth quarter. Deep Track Capital LP now owns 17,791,486 shares of the biopharmaceutical company's stock worth $227,197,000 after acquiring an additional 5,265,000 shares during the period. Cresset Asset Management LLC lifted its holdings in Dynavax Technologies by 5.1% during the fourth quarter. Cresset Asset Management LLC now owns 175,558 shares of the biopharmaceutical company's stock valued at $2,242,000 after purchasing an additional 8,539 shares in the last quarter. Finally, Crestline Management LP grew its position in shares of Dynavax Technologies by 78.3% in the fourth quarter. Crestline Management LP now owns 452,455 shares of the biopharmaceutical company's stock valued at $5,778,000 after purchasing an additional 198,685 shares during the period. 96.96% of the stock is owned by hedge funds and other institutional investors.

Dynavax Technologies Price Performance

Shares of DVAX stock traded up $0.26 during trading hours on Thursday, reaching $9.76. The company had a trading volume of 2,053,593 shares, compared to its average volume of 2,213,229. Dynavax Technologies Co. has a 12-month low of $9.22 and a 12-month high of $14.63. The company has a debt-to-equity ratio of 0.33, a quick ratio of 12.34 and a current ratio of 13.23. The company has a market capitalization of $1.17 billion, a price-to-earnings ratio of 54.22 and a beta of 1.26. The stock has a fifty day moving average of $11.16 and a 200-day moving average of $12.38.

Dynavax Technologies (NASDAQ:DVAX - Get Free Report) last issued its earnings results on Tuesday, May 6th. The biopharmaceutical company reported ($0.11) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.03 by ($0.14). Dynavax Technologies had a return on equity of 4.22% and a net margin of 9.85%. The company had revenue of $68.16 million during the quarter, compared to analyst estimates of $70.01 million. On average, equities analysts anticipate that Dynavax Technologies Co. will post 0.32 earnings per share for the current year.

Wall Street Analysts Forecast Growth

DVAX has been the subject of several research analyst reports. JMP Securities reduced their price target on shares of Dynavax Technologies from $33.00 to $31.00 and set a "market outperform" rating for the company in a research report on Wednesday, May 7th. HC Wainwright restated a "buy" rating and issued a $31.00 target price on shares of Dynavax Technologies in a research report on Friday, February 21st. The Goldman Sachs Group lowered their price target on Dynavax Technologies from $12.00 to $10.00 and set a "sell" rating on the stock in a research note on Thursday, April 17th. Wall Street Zen downgraded Dynavax Technologies from a "buy" rating to a "hold" rating in a research note on Tuesday, May 6th. Finally, William Blair restated an "outperform" rating on shares of Dynavax Technologies in a report on Friday, February 21st. One analyst has rated the stock with a sell rating, one has given a hold rating and three have issued a buy rating to the company. According to MarketBeat, Dynavax Technologies currently has a consensus rating of "Hold" and an average price target of $24.00.

Dynavax Technologies Company Profile

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.